Cargando…
505. Bezlotoxumab Reduces Recurrence of Clostridium difficile Infection in Immunocompromised Patients: Early Experience at a Tertiary Care Center
BACKGROUND: Bezlotoxumab (BEZ) was approved in 2017 for prevention of recurrent C. difficile infection (CDI), with a number needed to treat (NNT) of 10 reported in the registration trials. Little information is available on its effectiveness in high-risk populations. BEZ was added to the institution...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253614/ http://dx.doi.org/10.1093/ofid/ofy210.514 |